Adial pharmaceuticals provides update on regulatory strategy for ad04 for treatment of alcohol use disorder

Company to pursue path toward u.s. and european approvals; type c meeting with fda confirmed for q2 2023; plans in place to meet with multiple european regulatory authorities
ADIL Ratings Summary
ADIL Quant Ranking